🔗 Share this article

While the US continues making unprecedented changes to its vaccination recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations in the pandemic and has focused upon potential deaths following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Agency leaders had intended to reveal radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US at odds with a large portion of the international standard with insufficient data for public health gain. This reveal has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A New Direction at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon rolling back already-approved vaccines at the FDA.

Høeg has often pushed for ending certain pediatric immunization guidelines in the US to become more like Denmark, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccination policy – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious experience in pharmaceutical research, oversight or management, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, said Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who ran the center have had.”

This division has an immense workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one have to be supervised,” she explained. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management component to the role, which manages in excess of 5,000 staff members. “It’s a huge management job, if you execute it properly,” the former official concluded.

Response and Disputed Initiatives

Regarding questions about Høeg’s qualifications and whether this appointment represents greater collaboration among FDA leaders on vaccines, a press secretary stated that the “questions stem from flawed assumptions”.

“Her resume is consistent with the functions of her position,” the spokesperson said, noting the months Høeg spent advising the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a controversial one-day drug-approval program that allegedly worried her former heads. “By what process are these drugs being picked for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of all drugs, aside from shots.”

Established History on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, track record, critics observe. She published a analysis using non-validated crowd-sourced reports to assess the incidence of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the new government featured revising rules for novel immunizations and halting “unnecessary” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has according to sources proposed excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who commences with her preconceived notions and tailors the evidence to retrofit the data in a very deceptive, untruthful manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|